MA
NKTR icon

Montag & Associates’s Nektar Therapeutics NKTR Stock Holding History

Montag & Associates’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.5K Hold
250
– – ﹤0.01% 701
2026
Q1 		$18K Buy
+250
New +$14.2K ﹤0.01% 691
2025
Q4 		– Sell
-7
Closed -$399 – 1094
2025
Q3 		$399 Buy
+7
New +$232 ﹤0.01% 1096

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Montag & Associates's NKTR Position: Q2 2026 in Review

Montag & Associates held its Nektar Therapeutics (NKTR) position steady in Q2 2026 at 250 shares worth $17.5K. The position accounts for ﹤0.01% of the portfolio, ranked #701.

Montag & Associates first reported a position in NKTR in Q3 2025 and has held it in 3 quarters since. The position peaked at $18K in Q1 2026. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Montag & Associates held 250 shares of Nektar Therapeutics worth $17.5K as of Q2 2026.
  • Montag & Associates left its Nektar Therapeutics share count unchanged in Q2 2026.
  • Nektar Therapeutics made up ﹤0.01% of Montag & Associates's portfolio in Q2 2026, its #701 holding.
  • Montag & Associates first reported a position in Nektar Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Montag & Associates's Nektar Therapeutics position peaked at $18K in Q1 2026.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Montag & Associates's 13F filing for Q2 2026, filed 5 Aug 2026.